Hyperparathyroidism is an endocrine disorder due to overexpression of the parathyroid hormone, leading to multiple disturbances of metabolism. This case study presents some of the most difficult cases of hyperparathyroidism and considers the complete range of symptoms along with problems in diagnostic procedures and different treatment approaches followed in managing the condition. Based on comprehensive patient profiles and outcomes, the present study underlines the importance of personalized management and the involvement of many teams of experts to improve patient care.
Hyperparathyroidism can be classified into three forms of the disease: primary, secondary, and tertiary, each presenting with its clinical challenges. Primary hyperparathyroidism is growing in incidence due to improved detection procedures and the aging population. The symptoms are therefore harder to diagnose when mild or overlapping with other conditions. Within this case study, the complex nature of hyperparathyroidism will be deeply elaborated concerning certain specific patient cases that will establish the nuances of clinical presentation, diagnostic evaluation, and therapeutic interventions.
Case 1: Primary Hyperparathyroidism
Patient History
Age: 62 years
Gender: Female
Medical History: Hypertension, osteopenia, and previous nephrolithiasis.
Symptoms: Fatigue, increased thirst, frequent urination, and bone pain.
Physical Examination
Vital Signs: BP: 130/80 mmHg, HR: 72 bpm
Weight: 75 kg
Height: 160 cm
Laboratory Results
Serum Calcium: 12.2 mg/dL (elevated)
Serum Phosphorus: 2.5 mg/dL (low)
PTH Level: 150 pg/mL (elevated)
Vitamin D: 20 ng/mL (deficient)
Discussion of Case 1
This patient’s presentation of hypercalcemia, elevated PTH, and low phosphorus levels is indicative of primary hyperparathyroidism. The combination of symptoms such as fatigue and bone pain aligns with typical manifestations of the disease.
Diagnostic Approach
A comprehensive diagnostic approach was undertaken, including imaging studies. A neck ultrasound revealed a 2.5 cm parathyroid adenoma.
Treatment Strategy
The treatment plan included surgical intervention, specifically parathyroidectomy, which was discussed with the patient. Preoperative optimization of vitamin D levels was recommended to enhance postoperative recovery. The patient underwent successful surgery, with follow-up laboratory tests showing normalization of calcium and PTH levels. She reported significant improvements in energy levels and quality of life postoperatively.
Case 2: Secondary Hyperparathyroidism
Patient History
Age: 58 years
Gender: Male
Medical History: Chronic kidney disease (CKD) stage 4, diabetes mellitus type 2.
Symptoms: Muscle weakness, pruritus, and bone pain.
Physical Examination
Vital Signs: BP: 140/85 mmHg, HR: 78 bpm
Weight: 90 kg
Height: 175 cm
Laboratory Results
Serum Calcium: 8.0 mg/dL (low)
Serum Phosphorus: 6.0 mg/dL (elevated)
PTH Level: 300 pg/mL (significantly elevated)
Vitamin D: 15 ng/mL (deficient)
Discussion of Case 2
This patient presented with secondary hyperparathyroidism due to CKD. The low serum calcium, high phosphorus, and markedly elevated PTH are characteristic findings in this condition.
Diagnostic Approach
A bone density scan indicated osteitis fibrosa cystica, a common complication of secondary hyperparathyroidism.
Treatment Strategy
Management strategies focused on controlling phosphate levels through dietary modifications and phosphate binders. Additionally, calcitriol was initiated to help regulate calcium levels and suppress PTH secretion. The patient was educated on the importance of regular follow-ups and lab monitoring, resulting in improved symptoms and stabilization of biochemical parameters over time.
Case 3: Tertiary Hyperparathyroidism
Patient History
Age: 70 years
Gender: Female
Medical History: Long-standing renal failure requiring hemodialysis for five years.
Symptoms: Fatigue, lethargy, and bone pain.
Physical Examination
Vital Signs: BP: 135/90 mmHg, HR: 75 bpm
Weight: 68 kg
Height: 162 cm
Laboratory Results
Serum Calcium: 10.5 mg/dL (elevated)
Serum Phosphorus: 5.5 mg/dL (elevated)
PTH Level: 400 pg/mL (elevated)
Discussion of Case 3
In this case, tertiary hyperparathyroidism developed following long-term secondary hyperparathyroidism due to renal failure. The body’s compensatory mechanisms led to autonomous PTH secretion despite normalizing calcium levels.
Diagnostic Approach
A technetium-99m sestamibi scan identified hyperplastic parathyroid glands.
Treatment Strategy
The treatment involved parathyroidectomy, which was performed after careful evaluation of the patient’s overall health and surgical risks. Postoperative monitoring showed significant reductions in PTH levels and resolution of symptoms, illustrating the effectiveness of surgical intervention in managing tertiary hyperparathyroidism.
This case study highlights the difficulties that arise in diagnosing and managing hyperparathyroidism according to its different forms. It requires individualized treatment taking into account the underlying cause, symptoms, and the general health status of each patient to ensure effective treatment. Here, a team involving endocrinologists, nephrologists, and surgeons comprises each other to provide optimized care and a better quality of life for patients.
Silverberg, S. J., et al. (2003). A 15-year prospective study of primary hyperparathyroidism. Journal of Bone and Mineral Research, 18(4), 723-728.
Fuleihan, G. E., et al. (2015). The epidemiology of primary hyperparathyroidism. Bone, 85, 54-60.
Lammert, M., et al. (2016). Management of secondary and tertiary hyperparathyroidism in chronic kidney disease: An update. Nephrology Dialysis Transplantation, 31(3), 393-400.
Lichtenstein, A. H., et al. (2008). Nutritional considerations in the management of chronic kidney disease. Clinical Journal of the American Society of Nephrology, 3(5), 1483-1491.
Bilezikian, J. P., et al. (2016). Guidelines for the management of asymptomatic primary hyperparathyroidism: A summary statement from the Fourth International Workshop. Journal of Clinical Endocrinology & Metabolism, 101(2), 286-300.
Reddy, K. S., et al. (2010). Hyperparathyroidism and bone disease. Clinical Reviews in Bone and Mineral Metabolism, 8(1), 9-21.
Peacock, M. (2010). Primary hyperparathyroidism and its management. Clinical Medicine, 10(3), 290-294.
Raisz, L. G., et al. (2005). Pathophysiology of secondary hyperparathyroidism. Endocrine Reviews, 26(2), 230-240.
Thakker, R. V., et al. (2012). Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). The Journal of Clinical Endocrinology & Metabolism, 97(9), 2949-2966.
Garrahy, A., et al. (2015). Managing patients with chronic kidney disease and secondary hyperparathyroidism: An endocrinologist's perspective. Clinical Diabetes and Endocrinology, 1(1), 1-8.
Read more such content on @ Hidoc Dr | Medical Learning App for Doctors
1.
There has been a recent decrease in the risk of a recurrence of colorectal cancer in stage I to III cases.
2.
In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.
3.
Recurrent UTIs impact eGFR in children with vesicoureteral reflux
4.
Month-Long Wait Times Caused by US Physician Shortage.
5.
Pharyngoesophageal junction cancer is not a good candidate for endoscopically assisted transoral surgery.
1.
A Closer Look at Poorly Differentiated Carcinoma: Uncovering its Complexities
2.
The Importance of Early Detection in Angiosarcoma: A Story of Survival
3.
Leukemia in Focus: Tools, Trials, and Therapy Strategies for Modern Medical Practice
4.
New Research Advances in the Treatment of Multiple Myeloma and Plasmacytoma
5.
Managing KRAS Inhibitor Toxicities: Focus on Rash and Beyond
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Incidence of Lung Cancer- An Overview to Understand ALK Rearranged NSCLC
2.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part III
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part III
4.
An Eagles View - Evidence-based Discussion on Iron Deficiency Anemia- Panel Discussion IV
5.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part V
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation